Yes, investing in speculative stocks—such as early-stage biotechnology firms, pre-revenue tech companies, or low-cap equities—carries an exceptionally high degree of financial risk. These assets frequently experience extreme price volatility, sharp drawdowns, and severe capital loss potential because their valuations depend heavily on unproven future milestones, regulatory approvals, or clinical trial outcomes rather than stable earnings.